Adverse Drug Reaction Classification System

ADR Ontology
ADR Term Focal segmental glomerulosclerosis
ADR ID BADD_A06461
ADR Hierarchy
20      Renal and urinary disorders
20.05      Nephropathies
20.05.01      Glomerulonephritis and nephrotic syndrome
20.05.01.003      Focal segmental glomerulosclerosis
Description A clinicopathological syndrome or diagnostic term for a type of glomerular injury that has multiple causes, primary or secondary. Clinical features include PROTEINURIA, reduced GLOMERULAR FILTRATION RATE, and EDEMA. Kidney biopsy initially indicates focal segmental glomerular consolidation (hyalinosis) or scarring which can progress to globally sclerotic glomeruli leading to eventual KIDNEY FAILURE. | Segmental glomerular degeneration with a glassy appearance (hyalinosis) caused by the accumulation of plasma proteins in the glomeruli. [MeSH]
MedDRA Code 10067757
MeSH ID D005923; D005923; D005923
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Focal & segmental glomerulosclerosis | Focal glomerulosclerosis | Focal segmental glomerulosclerosis | Glomerulosclerosis, Focal Segmental | Segmental Glomerulosclerosis, Focal | Glomerulosclerosis, Focal | Focal Glomerulosclerosis | Focal Segmental Glomerulosclerosis | Glomerulonephritis, Focal Sclerosing | Focal Sclerosing Glomerulonephritides | Focal Sclerosing Glomerulonephritis | Glomerulonephritides, Focal Sclerosing | Sclerosing Glomerulonephritides, Focal | Sclerosing Glomerulonephritis, Focal | Hyalinosis, Segmental Glomerular | Glomerular Hyalinosis, Segmental | Segmental Glomerular Hyalinosis | Hyalinosis, Segmental | Segmental Hyalinosis
ADR Related Proteins
Protein Name UniProt AC TTD Target ID
Not AvailableNot AvailableNot Available
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D00551Cyclosporine0.001298%
BADD_D00858Everolimus0.000730%
BADD_D01042Griseofulvin0.003837%
BADD_D01119Ibrutinib0.000533%
BADD_D01661Pamidronate disodium--
BADD_D01662Pamidronic acid0.000564%
BADD_D02028Sirolimus--
BADD_D02058Sorafenib0.000799%
BADD_D02105Tacrolimus0.009226%
BADD_D02155Tenofovir disoproxil0.017772%
BADD_D02264Trastuzumab--
BADD_D02414Mesalazine0.000850%
The 1th Page    1    Total 1 Pages